Vancouver, British Columbia / December 10, 2020 – Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8), is pleased to report that its US subsidiary, Advanced Proteome Therapeutics Inc. (“APTI”), is providing an update on its radioimaging and biodistribution study.
APTI reports that previously announced collaboration with Dr. Brian Zeglis at the City University of New York to test APTI’s site-selective conjugation technology in the rapidly growing field of antibody radioisotope conjugates (ARCs) has produced preliminary radioimaging and biodistribution results. This study is comparing APT site-selective conjugation technology to non-site-selective lysine conjugation utilizing the antibody pertuzumab in a HER2+ breast cancer model. Both APTI and the control constructs maintain an equivalent radioisotope to antibody ratio and utilize the same linker technology; thus, the key difference between the constructs are the sites of linker-antibody conjugation. Preliminary results in a subset of animals have now shown, for the APTI construct, an impressive signal with improvement in tumor enhancement at multiple time points with PET imaging and average tumor radioactivity almost double the control construct in biodistribution studies. These findings are consistent with greater delivery of APT constructs to the tumor with equivalent dose administered. This study will continue as planned with larger cohorts early in the new year.
This data continues to support the improved in vivo behavior of constructs using APTI site-selective conjugation technology. As data continues to be generated this could support development of ARCs for imaging purposes. Additionally, this data may be inferred to apply to behavior of therapeutic antibody drug conjugates with greater delivery of drug to tumor and less to healthy tissue leading to better outcomes with less toxicity.
Dr. Benjamin Krantz, Director of APTI commented “I am extremely excited by these early results. They are consistent with all prior comparative studies that have continually shown superior performance of constructs using APTI conjugation technology. Additional data could support development of ARCs with APTI technology, but more importantly will also support our assertion of improved behavior of APTI therapeutic constructs. I am looking forward to the final results in larger cohorts.”
Paul Woodward, CEO of the Company stated “This is another instance of APTI’s conjugation technology improving the behavior of antibody conjugate constructs and supporting our view of this technology as the industry gold standard conjugation technology. We plan to continue to generate and disseminate data to promote our findings and stimulate collaborator interest.”
ABOUT THE COMPANY:
Advanced Proteome Therapeutics Corporation, through its subsidiary, Advanced Proteome Therapeutics Inc., has invented proprietary protein conjugation technology which enables the development of superior antibody-drug conjugates through improved site-specific labeling, drug-antibody ratio control and enabling of combination payloads. The technology has compelling pre-clinical data demonstrating improved homogeneity and increased in-vivo potency relative to current state of the art linker technology. The Company believes that the technology will enable the development of safer and more potent antibody-drug conjugate therapeutics and is pursuing licensing and partnership opportunities to advance development and create shareholder value.
FOR FURTHER INFORMATION PLEASE CONTACT:
Advanced Proteome Therapeutics Corporation
President and CEO
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release contains forward-looking statements relating to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “intends”, “anticipates”, “expects” and similar expressions. All statements other than statements of historical fact included in this release, including, without limitation, statements regarding the future plans and objectives of the Company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations are risks detailed from time to time in the filings made by the Company with securities regulators.
Readers are cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties and other factors, many of which are beyond the control of the Company. As a result, the Company cannot guarantee that any forward-looking statement will materialize, and readers should not place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will only update or revise publicly any of the included forward-looking statements as expressly required by Canadian securities law.